SOUTH SAN FRANCISCO, CA, May 06, 2015 (Marketwired via COMTEX) -- Theravance, Inc. THRX, -0.39% today reported financial results for the first quarter ended March 31, 2015. Royalties earned on net sales of RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R) from Glaxo Group Limited (GSK) during the first quarter 2015 were $10.1 million, and income from operations increased to $0.7 million, compared to $0.1 million in the fourth quarter of 2014. Adjusted EBITDA for the first quarter of 2015 was $6.2 million. Net loss for the first quarter 2015 was $10.7 million or $0.09 per share. Cash and cash equivalents, short-term investments, and marketable securities totaled $255.1 million as of March 31, 2015.
Help employers find you! Check out all the jobs and post your resume.
